Fiche centre
University of Alberta
Edmonton — Canada
Essais liés15clinical trials
VilleEdmontonlocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06570473
Essais cliniques associés
15| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Mechanical Endovascular Thrombectomy | Accident vasculaire cérébral | Phase 3 | NCT07906275 | INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | NOT_YET_RECRUITING |
| Tenecteplase | Accident vasculaire cérébral | Phase 3 | NCT06320431 | ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | RECRUITING |
| Tenecteplase or Alteplase- depending upon availability at each treating centre | Accident vasculaire cérébral | Phase 3 | NCT07687056 | ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | RECRUITING |
| Empagliflozin | Insuffisance cardiaque | Phase 2 | NCT06570473 | CRAVE — Feasibility Trial for a Right Ventricular Failure Platform Trial | RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| Pozelimab + Cemdisiran | Myasthénie | Phase 3 | NCT05070858 | NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| SRP-1001 for Injection | Myopathies | Phase 1/2 | NCT06131983 | Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 | ENROLLING_BY_INVITATION |
| SRP-1003 IV Infusion | Myopathies | Phase 1/2 | NCT06138743 | Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | ENROLLING_BY_INVITATION |
| Eptinezumab | Migraine | Phase 3 | NCT04965675 | PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Fosigotifator | Sclérose latérale amyotrophique | Phase 1 | NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | TERMINATED |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |